Global Health Q4 Results Review - Mature Hospitals Drive YoY Earnings Growth: Motilal Oswal
Indore back on track/Noida to commence operations in Q4 FY25/Q1 FY2621-05-2024
21-05-2024
Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find the below link of Audio Recording of Earnings Conference Call held on Monday, May 20, 2024 at 2:00 P.M. (IST) hosted by JM Financial, for the fourth quarter and financial year ended March 31, 2024 results of the Company : https://www.medanta.org/investor_relations/financial-information/audiovideo-recording-earningsquarterly-calls20-05-2024
Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
we would like to inform you that meeting with the representatives of Investor/Analyst is scheduled with the Management of the Company, as enclosed20-05-2024
Global Health Results Earnings Call for Q4FY24
Conference Call with Global Health Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.20-05-2024
Q4FY24 Quarterly & FY24 Annual Result Announced for Global Health Ltd.
Healthcare Facilities company Global Health announced consolidated Q4FY24 & FY24 results: FY24 Financial Highlights: Total income of Rs 33,498 million, growth of 21% YoY EBITDA of Rs 8,737 million compared to Rs 6,771 million, growth of 29% YoY EBITDA margins improved by 154 bps to 26.1% Profit after tax of Rs 4,781 million, growth of 47% YoY Net cash surplus of Rs 7,720 million Average occupied bed days increased by 14% YoY, representing an occupancy of 62% on increased bed capacity In-patients count increased by 15%; Out-patient count increased by 18% in FY24 ARPOB grew by 4.7% to Rs 61,890 Developing hospitals revenue share of consolidated revenue increased from 27% in FY23 to 30% in FY24 amounting to Rs 9,948 million. Developing hospital EBITDA share of consolidated EBITDA increased from 32% in FY23 to 37% in FY24 amounting to Rs 3,208 million During the period, International Patients Revenue increased by 24% to Rs 1,935 million, driven by increased volume in international patient admissions and higher realizations In house OPD Pharmacy business continues to register strong growth. Revenue increased by 32% from Rs 850 million in FY23 to Rs 1,121 million in FY24 Q4FY24 Financial Highlights: Total income of Rs 8,361 million; growth of 14% YoY EBITDA of Rs 2,068 million; growth of 8% YoY EBITDA margins remained stable at 24.7% Profit after tax of Rs 1,273 million; growth of 26% YoY Average occupied bed days increased by 9% YoY, representing an occupancy of 59% on increased bed capacity ARPOB grew by 4% to Rs 63,063; In-patient count increased by 10% YoY; Out-patient count increased by 11% YoY Commenting on FY2024 results, Pankaj Sahni, Group CEO and Director said: “I am pleased to inform that keeping with our consistent focus on quality care, Medanta has been recognized by Newsweek as India's 'Best Private Hospital' for the fifth consecutive year. Medanta Gurugram is also the only Indian private hospital to feature in the top 200 hospitals in the world. The continued focus on providing our patients with the highest quality of care has enabled Medanta to deliver strong financial results during the year. We remain dedicated to executing our core strategy and delivering on our upcoming projects. Medanta is well-positioned to drive near-term growth with calibrated bed capacity expansions at existing hospitals and new facilities.” Result PDF20-05-2024
Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication for Financial Results of the Company for March 31, 2024.18-05-2024
Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the Quarter and Financial Year ended March 31, 2024 Results of the Company.17-05-2024
Global Health Ltd - 543654 - Key Performance Indicators (Kpis) For FY 2023-24.
Pursuant to SEBI ICDR Regulations, please find the Key Performance Indicators for FY 2023-24.17-05-2024
Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release for Financial Year ended March 31, 2024 Results of the Company.17-05-2024
Global Health Ltd - 543654 - Statement Of Deviation/Variation In Utilization Of Funds Raised Through Initial Public Offer ('IPO'), For The Quarter Ended March 31, 2024.
Statement of Deviation for the Quarter ended March 31, 202417-05-2024